Mechanism

How it works

Cagrilintide binds to amylin receptors (AMY1R, AMY2R, AMY3R), which are heterodimers of the calcitonin receptor and receptor activity-modifying proteins (RAMPs 1, 2, or 3), activating cAMP-mediated signaling pathways in the hypothalamus, area postrema, and nucleus of the solitary tract. This activation suppresses glucagon secretion, slows gastric emptying, and reduces food intake by enhancing central satiety signaling. The fatty acid acylation of cagrilintide extends its half-life to approximately 7 days, enabling once-weekly subcutaneous dosing.

Reported in research

Benefits

Significant and sustained body weight reduction (up to ~10–15% in phase 2 trials as monotherapy; greater reductions in combination with semaglutide)
Reduction in caloric intake through centrally mediated appetite suppression and enhanced satiety
Slowing of gastric emptying, leading to improved postprandial glucose control
Suppression of inappropriate glucagon secretion, supporting glycemic regulation in type 2 diabetes

Context, not a prescription

Dosing

Typical range: 0.3 mg/week escalating to up to 4.5 mg/week (clinical trial protocol); research vials dosed per investigator protocol (Subcutaneous)
Cycle length: 16–32 weeks (per clinical trial protocols; long-term use under investigation)
Half-life: ~7 days

Safety

Side effects & contraindications

Possible side effects

Nausea (most common, particularly during dose escalation)
Vomiting
Diarrhea
Constipation
Decreased appetite beyond intended effect
Injection site reactions (erythema, induration)

Contraindications

Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — caution extrapolated from calcitonin receptor agonism class
Severe gastrointestinal disease (e.g., gastroparesis) due to gastric emptying inhibition
Pregnancy or breastfeeding (insufficient safety data)
Known hypersensitivity to cagrilintide or any excipient

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Reduced hunger and food cravings, smaller comfortable portion sizes, gradual reduction in body weight, and improved blood sugar stability after meals.

How it works

Think of amylin as a 'full signal' light that your pancreas switches on after a meal — cagrilintide is like a longer-lasting version of that light that stays on all week, keeping your brain in 'I'm satisfied' mode more consistently.

After injection under the skin, cagrilintide slowly enters the bloodstream and travels to appetite-control centres in the brain (particularly the hypothalamus and brainstem). There it activates receptors that lower your desire to eat, reduce the hormone glucagon (which raises blood sugar), and slow digestion so you feel fuller for longer after smaller meals.

What to expect

Appetite suppression effects may be noticed within the first 1–2 weeks; significant weight changes typically become apparent after 4–8 weeks of consistent dosing.

Week 1: First injection; mild nausea may occur as the body adjusts. Appetite may begin to feel slightly reduced.
Weeks 2-4: Nausea typically lessens. Satiety signals strengthen, meal portions naturally decrease, and early weight changes (1–3 lbs) may be noticed.
Weeks 4-8: More pronounced and consistent weight reduction. Energy levels may stabilise, and post-meal fullness becomes reliably longer-lasting.

Good to know

Start at the lowest dose and increase slowly to allow your body to adjust and minimise nausea
Take injections at the same time each week and rotate injection sites to reduce local reactions

Staying safe

Nausea, especially in the first few weeks or after dose increases
Occasional vomiting or upset stomach
Loose stools or constipation

Avoid if you have:

People with a history of thyroid cancer (medullary type) in themselves or their family
Pregnant or breastfeeding individuals
Anyone with severe stomach motility disorders

Overview

Physiological changes include: reduction in 24-hour energy intake (estimated 15–25% in clinical settings), blunting of postprandial glucagon excursions, delayed gastric emptying measurable by paracetamol absorption tests, reduction in fasting and postprandial insulin requirements (secondary to improved glucose handling), and progressive reduction in fat mass (predominantly visceral adiposity) with relative preservation of lean mass compared to caloric restriction alone.

How it works

If normal amylin is a short-burst radio signal telling the brain to stop eating, cagrilintide is a continuous broadcast tower — the fatty acid chain anchors it to circulating albumin, turning a brief postprandial pulse into a persistent, week-long satiety signal with the same receptor language.

Following subcutaneous injection, cagrilintide undergoes slow absorption (Tmax ~2–3 days) with high plasma protein binding via fatty acid–albumin interactions, achieving steady-state concentrations after approximately 4 weeks of weekly dosing. It crosses a limited blood-brain barrier at circumventricular organs (area postrema lacks a tight blood-brain barrier), engaging AMY receptors to: (1) inhibit glucagon secretion from pancreatic alpha-cells; (2) delay gastric emptying via vagal efferent modulation; (3) reduce hypothalamic NPY/AgRP neuropeptide expression; and (4) potentiate GLP-1 receptor signalling when co-administered, producing additive to synergistic weight-loss effects in CagriSema trials.

Onset & timeline

Pharmacokinetically, plasma concentrations rise over days 1–3 post-injection. Receptor occupancy sufficient to suppress glucagon and reduce meal size is estimated within 24–48 hours of first dose. Steady-state is achieved at approximately week 4–5 of weekly injections. Clinically meaningful appetite reduction is typically reported by week 2 and peak weight loss trajectory is established by weeks 8–12.

Days 1-3: Cagrilintide Tmax reached ~48–72 hours post-injection; early receptor engagement at area postrema; mild nausea may manifest as cAMP signalling activates brainstem emetic pathways.
Weeks 1-2: Measurable reduction in ad libitum caloric intake; glucagon suppression detectable in postprandial glucose profiles; steady titration to higher dose tier if tolerated.
Weeks 2-8: Approach to pharmacokinetic steady-state (~week 4-5); cumulative weight loss becomes clinically significant; visceral fat mobilisation accelerates; metabolic parameters (HbA1c, fasting glucose, triglycerides) trend toward improvement.

Getting the most from it

Implement a structured dose-escalation protocol (e.g., 0.3 → 0.6 → 1.2 → 2.4 → 4.5 mg/week over 16+ weeks) to minimise GI adverse events
Monitor serum calcitonin at baseline and periodically given receptor pharmacology
Assess pancreatic enzyme levels (lipase, amylase) if persistent abdominal pain develops
Avoid combining with pramlintide or other amylin agonists due to pharmacodynamic overlap

Common side effects

Nausea (dose-dependent, incidence ~40–60% during titration phase; diminishes at maintenance dose over 4–8 weeks)
Vomiting (~15–25% during escalation)
Constipation or diarrhoea (gastrointestinal transit time alteration)
Transient injection site erythema and induration

Mechanism of action

Cagrilintide is a C-18 fatty diacid-acylated analogue of human amylin (islet amyloid polypeptide, IAPP) engineered for extended half-life via albumin binding. It acts as a full agonist at amylin receptors — heterodimeric complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins RAMP1 (AMY1R), RAMP2 (AMY2R), or RAMP3 (AMY3R) — activating Gs-coupled cAMP/PKA and downstream MAPK signalling pathways. CNS targets include the area postrema, nucleus of the solitary tract, and lateral hypothalamus, collectively reducing meal size, suppressing glucagon secretion in a glucose-dependent manner, inhibiting gastric emptying, and modulating reward-related feeding behaviours. The acylation strategy mirrors that used for semaglutide and insulin degludec, conferring a terminal half-life of ~7 days suitable for once-weekly dosing.

Following subcutaneous injection, cagrilintide undergoes slow absorption (Tmax ~2–3 days) with high plasma protein binding via fatty acid–albumin interactions, achieving steady-state concentrations after approximately 4 weeks of weekly dosing. It crosses a limited blood-brain barrier at circumventricular organs (area postrema lacks a tight blood-brain barrier), engaging AMY receptors to: (1) inhibit glucagon secretion from pancreatic alpha-cells; (2) delay gastric emptying via vagal efferent modulation; (3) reduce hypothalamic NPY/AgRP neuropeptide expression; and (4) potentiate GLP-1 receptor signalling when co-administered, producing additive to synergistic weight-loss effects in CagriSema trials.

Pharmacodynamics

Pharmacokinetically, plasma concentrations rise over days 1–3 post-injection. Receptor occupancy sufficient to suppress glucagon and reduce meal size is estimated within 24–48 hours of first dose. Steady-state is achieved at approximately week 4–5 of weekly injections. Clinically meaningful appetite reduction is typically reported by week 2 and peak weight loss trajectory is established by weeks 8–12.

Physiological changes include: reduction in 24-hour energy intake (estimated 15–25% in clinical settings), blunting of postprandial glucagon excursions, delayed gastric emptying measurable by paracetamol absorption tests, reduction in fasting and postprandial insulin requirements (secondary to improved glucose handling), and progressive reduction in fat mass (predominantly visceral adiposity) with relative preservation of lean mass compared to caloric restriction alone.

Timeline

Days 1-3: Cagrilintide Tmax reached ~48–72 hours post-injection; early receptor engagement at area postrema; mild nausea may manifest as cAMP signalling activates brainstem emetic pathways.
Weeks 1-2: Measurable reduction in ad libitum caloric intake; glucagon suppression detectable in postprandial glucose profiles; steady titration to higher dose tier if tolerated.
Weeks 2-8: Approach to pharmacokinetic steady-state (~week 4-5); cumulative weight loss becomes clinically significant; visceral fat mobilisation accelerates; metabolic parameters (HbA1c, fasting glucose, triglycerides) trend toward improvement.

Comparisons

Cagrilintide (monotherapy) — effectiveness High, safety Good, cost $$$, Medium to use
CagriSema (cagrilintide + semaglutide) — effectiveness Very High, safety Good, cost $$$$, Medium to use
Pramlintide (Symlin) — effectiveness Moderate, safety Good, cost $$, Low to use

Adverse effects

Common:

Nausea (dose-dependent, incidence ~40–60% during titration phase; diminishes at maintenance dose over 4–8 weeks)
Vomiting (~15–25% during escalation)
Constipation or diarrhoea (gastrointestinal transit time alteration)
Transient injection site erythema and induration

Rare:

Calcitonin receptor-mediated hypocalcaemia risk (theoretical; not prominently observed in trials at therapeutic doses)
Acute pancreatitis (class-level concern shared with amylin/GLP-1 axis drugs; reported rarely in trial populations)
Hypoglycaemia when combined with insulin secretagogues

Contraindications & risk mitigation

Contraindicated in:

Individuals with personal or family history of medullary thyroid carcinoma or MEN2 (calcitonin receptor agonism class caution)
Patients with severe gastroparesis or obstructive gastrointestinal pathology
Individuals with renal impairment (eGFR <30 mL/min/1.73 m²) — pharmacokinetics not fully established
Concurrent use with other gastric-emptying inhibitors without careful monitoring

Implement a structured dose-escalation protocol (e.g., 0.3 → 0.6 → 1.2 → 2.4 → 4.5 mg/week over 16+ weeks) to minimise GI adverse events
Monitor serum calcitonin at baseline and periodically given receptor pharmacology
Assess pancreatic enzyme levels (lipase, amylase) if persistent abdominal pain develops
Avoid combining with pramlintide or other amylin agonists due to pharmacodynamic overlap

Qué hace

Reduced hunger and food cravings, smaller comfortable portion sizes, gradual reduction in body weight, and improved blood sugar stability after meals.

Cómo funciona

Think of amylin as a 'full signal' light that your pancreas switches on after a meal — cagrilintide is like a longer-lasting version of that light that stays on all week, keeping your brain in 'I'm satisfied' mode more consistently.

After injection under the skin, cagrilintide slowly enters the bloodstream and travels to appetite-control centres in the brain (particularly the hypothalamus and brainstem). There it activates receptors that lower your desire to eat, reduce the hormone glucagon (which raises blood sugar), and slow digestion so you feel fuller for longer after smaller meals.

Qué esperar

Appetite suppression effects may be noticed within the first 1–2 weeks; significant weight changes typically become apparent after 4–8 weeks of consistent dosing.

Week 1: First injection; mild nausea may occur as the body adjusts. Appetite may begin to feel slightly reduced.
Weeks 2-4: Nausea typically lessens. Satiety signals strengthen, meal portions naturally decrease, and early weight changes (1–3 lbs) may be noticed.
Weeks 4-8: More pronounced and consistent weight reduction. Energy levels may stabilise, and post-meal fullness becomes reliably longer-lasting.

Bueno saber

Start at the lowest dose and increase slowly to allow your body to adjust and minimise nausea
Take injections at the same time each week and rotate injection sites to reduce local reactions

Manteniéndose seguro

Nausea, especially in the first few weeks or after dose increases
Occasional vomiting or upset stomach
Loose stools or constipation

Evitar si tienes:

People with a history of thyroid cancer (medullary type) in themselves or their family
Pregnant or breastfeeding individuals
Anyone with severe stomach motility disorders

Descripción general

Physiological changes include: reduction in 24-hour energy intake (estimated 15–25% in clinical settings), blunting of postprandial glucagon excursions, delayed gastric emptying measurable by paracetamol absorption tests, reduction in fasting and postprandial insulin requirements (secondary to improved glucose handling), and progressive reduction in fat mass (predominantly visceral adiposity) with relative preservation of lean mass compared to caloric restriction alone.

Cómo funciona

If normal amylin is a short-burst radio signal telling the brain to stop eating, cagrilintide is a continuous broadcast tower — the fatty acid chain anchors it to circulating albumin, turning a brief postprandial pulse into a persistent, week-long satiety signal with the same receptor language.

Following subcutaneous injection, cagrilintide undergoes slow absorption (Tmax ~2–3 days) with high plasma protein binding via fatty acid–albumin interactions, achieving steady-state concentrations after approximately 4 weeks of weekly dosing. It crosses a limited blood-brain barrier at circumventricular organs (area postrema lacks a tight blood-brain barrier), engaging AMY receptors to: (1) inhibit glucagon secretion from pancreatic alpha-cells; (2) delay gastric emptying via vagal efferent modulation; (3) reduce hypothalamic NPY/AgRP neuropeptide expression; and (4) potentiate GLP-1 receptor signalling when co-administered, producing additive to synergistic weight-loss effects in CagriSema trials.

Inicio y cronología

Pharmacokinetically, plasma concentrations rise over days 1–3 post-injection. Receptor occupancy sufficient to suppress glucagon and reduce meal size is estimated within 24–48 hours of first dose. Steady-state is achieved at approximately week 4–5 of weekly injections. Clinically meaningful appetite reduction is typically reported by week 2 and peak weight loss trajectory is established by weeks 8–12.

Days 1-3: Cagrilintide Tmax reached ~48–72 hours post-injection; early receptor engagement at area postrema; mild nausea may manifest as cAMP signalling activates brainstem emetic pathways.
Weeks 1-2: Measurable reduction in ad libitum caloric intake; glucagon suppression detectable in postprandial glucose profiles; steady titration to higher dose tier if tolerated.
Weeks 2-8: Approach to pharmacokinetic steady-state (~week 4-5); cumulative weight loss becomes clinically significant; visceral fat mobilisation accelerates; metabolic parameters (HbA1c, fasting glucose, triglycerides) trend toward improvement.

Cómo aprovecharlo al máximo

Implement a structured dose-escalation protocol (e.g., 0.3 → 0.6 → 1.2 → 2.4 → 4.5 mg/week over 16+ weeks) to minimise GI adverse events
Monitor serum calcitonin at baseline and periodically given receptor pharmacology
Assess pancreatic enzyme levels (lipase, amylase) if persistent abdominal pain develops
Avoid combining with pramlintide or other amylin agonists due to pharmacodynamic overlap

Efectos secundarios comunes

Nausea (dose-dependent, incidence ~40–60% during titration phase; diminishes at maintenance dose over 4–8 weeks)
Vomiting (~15–25% during escalation)
Constipation or diarrhoea (gastrointestinal transit time alteration)
Transient injection site erythema and induration

Mecanismo de acción

Cagrilintide is a C-18 fatty diacid-acylated analogue of human amylin (islet amyloid polypeptide, IAPP) engineered for extended half-life via albumin binding. It acts as a full agonist at amylin receptors — heterodimeric complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins RAMP1 (AMY1R), RAMP2 (AMY2R), or RAMP3 (AMY3R) — activating Gs-coupled cAMP/PKA and downstream MAPK signalling pathways. CNS targets include the area postrema, nucleus of the solitary tract, and lateral hypothalamus, collectively reducing meal size, suppressing glucagon secretion in a glucose-dependent manner, inhibiting gastric emptying, and modulating reward-related feeding behaviours. The acylation strategy mirrors that used for semaglutide and insulin degludec, conferring a terminal half-life of ~7 days suitable for once-weekly dosing.

Following subcutaneous injection, cagrilintide undergoes slow absorption (Tmax ~2–3 days) with high plasma protein binding via fatty acid–albumin interactions, achieving steady-state concentrations after approximately 4 weeks of weekly dosing. It crosses a limited blood-brain barrier at circumventricular organs (area postrema lacks a tight blood-brain barrier), engaging AMY receptors to: (1) inhibit glucagon secretion from pancreatic alpha-cells; (2) delay gastric emptying via vagal efferent modulation; (3) reduce hypothalamic NPY/AgRP neuropeptide expression; and (4) potentiate GLP-1 receptor signalling when co-administered, producing additive to synergistic weight-loss effects in CagriSema trials.

Farmacodinamia

Pharmacokinetically, plasma concentrations rise over days 1–3 post-injection. Receptor occupancy sufficient to suppress glucagon and reduce meal size is estimated within 24–48 hours of first dose. Steady-state is achieved at approximately week 4–5 of weekly injections. Clinically meaningful appetite reduction is typically reported by week 2 and peak weight loss trajectory is established by weeks 8–12.

Physiological changes include: reduction in 24-hour energy intake (estimated 15–25% in clinical settings), blunting of postprandial glucagon excursions, delayed gastric emptying measurable by paracetamol absorption tests, reduction in fasting and postprandial insulin requirements (secondary to improved glucose handling), and progressive reduction in fat mass (predominantly visceral adiposity) with relative preservation of lean mass compared to caloric restriction alone.

Cronología

Days 1-3: Cagrilintide Tmax reached ~48–72 hours post-injection; early receptor engagement at area postrema; mild nausea may manifest as cAMP signalling activates brainstem emetic pathways.
Weeks 1-2: Measurable reduction in ad libitum caloric intake; glucagon suppression detectable in postprandial glucose profiles; steady titration to higher dose tier if tolerated.
Weeks 2-8: Approach to pharmacokinetic steady-state (~week 4-5); cumulative weight loss becomes clinically significant; visceral fat mobilisation accelerates; metabolic parameters (HbA1c, fasting glucose, triglycerides) trend toward improvement.

Comparaciones

Cagrilintide (monotherapy) — efectividad High, seguridad Good, costo $$$, Medium de usar
CagriSema (cagrilintide + semaglutide) — efectividad Very High, seguridad Good, costo $$$$, Medium de usar
Pramlintide (Symlin) — efectividad Moderate, seguridad Good, costo $$, Low de usar

Efectos adversos

Comunes:

Nausea (dose-dependent, incidence ~40–60% during titration phase; diminishes at maintenance dose over 4–8 weeks)
Vomiting (~15–25% during escalation)
Constipation or diarrhoea (gastrointestinal transit time alteration)
Transient injection site erythema and induration

Raros:

Calcitonin receptor-mediated hypocalcaemia risk (theoretical; not prominently observed in trials at therapeutic doses)
Acute pancreatitis (class-level concern shared with amylin/GLP-1 axis drugs; reported rarely in trial populations)
Hypoglycaemia when combined with insulin secretagogues

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Individuals with personal or family history of medullary thyroid carcinoma or MEN2 (calcitonin receptor agonism class caution)
Patients with severe gastroparesis or obstructive gastrointestinal pathology
Individuals with renal impairment (eGFR <30 mL/min/1.73 m²) — pharmacokinetics not fully established
Concurrent use with other gastric-emptying inhibitors without careful monitoring

Implement a structured dose-escalation protocol (e.g., 0.3 → 0.6 → 1.2 → 2.4 → 4.5 mg/week over 16+ weeks) to minimise GI adverse events
Monitor serum calcitonin at baseline and periodically given receptor pharmacology
Assess pancreatic enzyme levels (lipase, amylase) if persistent abdominal pain develops
Avoid combining with pramlintide or other amylin agonists due to pharmacodynamic overlap

Reference data

Specifications

Molecular formula: C₁₄₉H₂₄₄N₄₀O₄₈S₂ (approximate; acylated analogue — exact formula proprietary)
Molecular weight: ~3400 Da (approximate)
Half-life: ~7 days
Route: Subcutaneous
Cycle length: 16–32 weeks (per clinical trial protocols; long-term use under investigation)
Storage: Store lyophilized peptide at -20°C; reconstituted solution should be kept at 2–8°C and used within 28 days. Protect from light and repeated freeze-thaw cycles.
Legal status: Investigational drug (not FDA or EMA approved as of 2024); available for licensed research use only. Not approved for human therapeutic use outside of clinical trials.

FAQ

Common questions

What is the mechanistic rationale for combining cagrilintide with semaglutide (CagriSema)?

Amylin and GLP-1 pathways are complementary but distinct. Amylin receptors (CTR/RAMP heterodimers) and GLP-1 receptors activate overlapping but non-identical downstream signalling networks in the hypothalamus and brainstem. Co-activation produces additive to synergistic reductions in food intake, greater suppression of glucagon, and enhanced weight loss. Phase 2 CagriSema data (NCT04982575) demonstrated ~15–17% weight loss at 32 weeks, exceeding either monotherapy.

How does cagrilintide differ from pramlintide (Symlin)?

Pramlintide is a short-acting amylin analogue requiring multiple daily injections (before each major meal). Cagrilintide uses fatty acid acylation for albumin binding and once-weekly dosing. Cagrilintide also has a modified amino acid sequence reducing amyloidogenicity risk relative to native IAPP.

What receptor selectivity profile does cagrilintide have?

Cagrilintide demonstrates agonism across AMY1R, AMY2R, and AMY3R with high affinity, and cross-reactivity with the calcitonin receptor (CTR) itself — explaining both the metabolic effects and the theoretical thyroid/bone-related class cautions observed with calcitonin pathway agonists.

What is the evidence level?

This compound is classified as Clinical evidence. Randomized controlled trial data in humans exists and supports use in specific contexts.

Research

Research & sources

Clinical evidence

Current evidence for Cagrilintide is rated as Clinical evidence. Human clinical evidence supports the reported effects.

1. Cagrilintide at 4·5 mg for once-weekly subcutaneous treatment of type 2 diabetes (SCALE CAMBER): a double-blind, randomised, placebo-controlled, dose-finding trial (2021) — The Lancet Diabetes & Endocrinology, doi:10.1016/S2213-8587(21)00318-6
2. CagriSema versus semaglutide, cagrilintide and placebo in participants with obesity: REDEFINE 1 (2024) — Novo Nordisk pipeline disclosure; ClinicalTrials.gov NCT04982575
3. Amylin receptor pharmacology and therapeutic potential (2020) — British Journal of Pharmacology — review of CTR/RAMP signalling

Explore

Often discussed alongside

Semaglutide · fat-loss Tirzepatide · fat-loss BPC-157 · healing